

Wolfgang Sadee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8088290/publications.pdf>

Version: 2024-02-01

125
papers

8,194
citations

57631

44
h-index

49773

87
g-index

129
all docs

129
docs citations

129
times ranked

10953
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions. JAMA - Journal of the American Medical Association, 2001, 286, 2270.	3.8	598
2	Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G. Journal of Biological Chemistry, 2005, 280, 32618-32624.	1.6	490
3	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenetics and Genomics, 2005, 15, 693-704.	0.7	419
4	Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20552-20557.	3.3	378
5	MicroRNAs modulate the chemosensitivity of tumor cells. Molecular Cancer Therapeutics, 2008, 7, 1-9.	1.9	357
6	Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance. Cancer Research, 2005, 65, 7446-7454.	0.4	283
7	Membrane Transporters and Channels. Cancer Research, 2004, 64, 4294-4301.	0.4	281
8	Innate Immune Gene Polymorphisms in Tuberculosis. Infection and Immunity, 2012, 80, 3343-3359.	1.0	258
9	MicroRNA expression profiles for the NCI-60 cancer cell panel. Molecular Cancer Therapeutics, 2007, 6, 1483-1491.	1.9	247
10	Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood, 2008, 112, 1013-1021.	0.6	187
11	Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci, 2000, 2, 29-41.	1.3	178
12	Pharmacogenetics/genomics and personalized medicine. Human Molecular Genetics, 2005, 14, R207-R214.	1.4	173
13	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenetics and Genomics, 2005, 15, 693-704.	0.7	166
14	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210.	2.3	164
15	Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer. Molecular Pharmacology, 2005, 67, 2173-2184.	1.0	142
16	The human zinc transporter SLC39A8 (Zip8) is critical in zinc-mediated cytoprotection in lung epithelia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L1127-L1136.	1.3	129
17	Dopamine Transporter Gene Variant Affecting Expression in Human Brain is Associated with Bipolar Disorder. Neuropsychopharmacology, 2011, 36, 1644-1655.	2.8	129
18	Intronic Polymorphisms Affecting Alternative Splicing of Human Dopamine D2 Receptor Are Associated with Cocaine Abuse. Neuropsychopharmacology, 2011, 36, 753-762.	2.8	128

#	ARTICLE	IF	CITATIONS
19	Accelerated communciation: Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. <i>Life Sciences</i> , 1994, 54, PL339-PL350.	2.0	122
20	Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. <i>Journal of Neurochemistry</i> , 2001, 77, 1590-1600.	2.1	118
21	Single Nucleotide Polymorphism Genotyping Using Allele-Specific PCR and Fluorescence Melting Curves. <i>BioTechniques</i> , 2003, 34, 1068-1072.	0.8	108
22	Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors. <i>Human Molecular Genetics</i> , 2006, 15, 2636-2649.	1.4	103
23	Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. <i>Human Molecular Genetics</i> , 2014, 23, 268-278.	1.4	101
24	Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. <i>FEBS Journal</i> , 1999, 260, 112-119.	0.2	100
25	Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model. <i>Brain Research</i> , 1980, 199, 49-61.	1.1	99
26	Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1). <i>AAPS Journal</i> , 2006, 8, E515-E520.	2.2	92
27	Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 781-791.	0.7	90
28	Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. <i>Life Sciences</i> , 2005, 76, 1427-1437.	2.0	88
29	Genetically Determined Interaction between the Dopamine Transporter and the D ₂ Receptor on Prefronto-Striatal Activity and Volume in Humans. <i>Journal of Neuroscience</i> , 2009, 29, 1224-1234.	1.7	87
30	Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics. , 2005, 106, 19-38.		83
31	Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 735-745.	0.7	83
32	Genetic Variants of the Human H ⁺ /Dipeptide Transporter PEPT2: Analysis of Haplotype Functions. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 1088-1096.	1.3	80
33	In Vivo Characterization of μ -Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1150-1162.	1.3	80
34	Different Effects of Opioid Antagonists on μ , κ , and δ -Opioid Receptors with and without Agonist Pretreatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 544-552.	1.3	80
35	Basal Signaling Activity of μ Opioid Receptor in Mouse Brain: Role in Narcotic Dependence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 512-520.	1.3	77
36	Protein therapeutics: new applications for pharmacogenetics. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 507-521.	21.5	76

#	ARTICLE	IF	CITATIONS
37	G-protein coupling of μ -opioid receptors (OP3): elevated basal signalling activity. <i>Biochemical Journal</i> , 2000, 348, 531-537.	1.7	69
38	Multiple Regulatory Variants Modulate Expression of 5-Hydroxytryptamine 2A Receptors in Human Cortex. <i>Biological Psychiatry</i> , 2013, 73, 546-554.	0.7	66
39	Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk. <i>PLoS ONE</i> , 2012, 7, e31930.	1.1	59
40	Nicotinic $\alpha 5$ receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms. <i>European Journal of Human Genetics</i> , 2011, 19, 76-83.	1.4	58
41	Missing heritability of common diseases and treatments outside the protein-coding exome. <i>Human Genetics</i> , 2014, 133, 1199-1215.	1.8	58
42	Whole transcriptome RNA-Seq allelic expression in human brain. <i>BMC Genomics</i> , 2013, 14, 571.	1.2	55
43	Alveolar macrophages from tuberculosis patients display an altered inflammatory gene expression profile. <i>Tuberculosis</i> , 2017, 107, 156-167.	0.8	54
44	Evolutionary relationships among G protein-coupled receptors using a clustered database approach. <i>AAPS PharmSci</i> , 2001, 3, 25-42.	1.3	50
45	AmpliSeq transcriptome analysis of human alveolar and monocyte-derived macrophages over time in response to <i>Mycobacterium tuberculosis</i> infection. <i>PLoS ONE</i> , 2018, 13, e0198221.	1.1	50
46	Growth Factor Signaling and Resistance to Cancer Chemotherapy. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1345-1354.	1.0	50
47	Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. <i>Pharmaceutical Research</i> , 2003, 20, 3-15.	1.7	49
48	Human proton/oligopeptide transporter (POT) genes: Identification of putative human genes using bioinformatics. <i>AAPS PharmSci</i> , 2000, 2, 76-97.	1.3	45
49	Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 652-664.	0.7	44
50	Basal phosphorylation of μ opioid receptor is agonist modulated and Ca ²⁺ -dependent. <i>FEBS Letters</i> , 1996, 387, 53-57.	1.3	41
51	Cheminformatics Analysis Identifies Cytotoxic Compounds Susceptible to Chemoresistance Mediated by Glutathione and Cystine/Glutamate Transport System xc-. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1896-1906.	2.9	41
52	Nuclear Ca ²⁺ /Calmodulin Translocation Activated by μ -Opioid (OP3) Receptor. <i>Journal of Neurochemistry</i> , 2002, 74, 1418-1425.	2.1	40
53	Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder. <i>Research in Developmental Disabilities</i> , 2014, 35, 1658-1665.	1.2	35
54	The $\alpha 5$ Nicotinic Receptor Regulome: Genomic Architecture, Regulatory Variants, and Clinical Associations. <i>Human Mutation</i> , 2017, 38, 112-119.	1.1	34

#	ARTICLE	IF	CITATIONS
55	Differential Effects of μ -Opioid Receptor Ligands on Ca^{2+} Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 1002-1012.	1.3	32
56	Gene expression profiling of brain samples from patients with Lewy body dementia. <i>Biochemical and Biophysical Research Communications</i> , 2016, 479, 875-880.	1.0	32
57	CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure. <i>Pharmaceutical Research</i> , 2017, 34, 1615-1625.	1.7	29
58	Transporter and ion channel gene expression after caco-2 cell differentiation using 2 different microarray technologies. <i>AAPS Journal</i> , 2004, 6, 35-44.	2.2	28
59	Cystine-Glutamate Transporter SLC7A11 Mediates Resistance to Geldanamycin but Not to 17-(Allylamino)-17-demethoxygeldanamycin. <i>Molecular Pharmacology</i> , 2007, 72, 1637-1646.	1.0	28
60	RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. <i>BMC Genomics</i> , 2015, 16, 990.	1.2	28
61	G-protein coupling of μ -opioid receptors (OP3): elevated basal signalling activity. <i>Biochemical Journal</i> , 2000, 348, 531.	1.7	27
62	Elemental Ingredients in the Macrophage Cocktail: Role of ZIP8 in Host Response to Mycobacterium tuberculosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2375.	1.8	27
63	Residues Specifically Involved in Down-Regulation but Not Internalization of the m1 Muscarinic Acetylcholine Receptor. <i>Journal of Neurochemistry</i> , 1997, 68, 601-609.	2.1	26
64	Expression and splicing of ABC and SLC transporters in the human blood-brain barrier measured with RNAseq. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 103, 47-51.	1.9	26
65	Ligand-Free Estrogen Receptor α (ESR1) as Master Regulator for the Expression of CYP3A4 and Other Cytochrome P450 Enzymes in the Human Liver. <i>Molecular Pharmacology</i> , 2019, 96, 430-440.	1.0	26
66	Prediction of Anticancer Drug Potency from Expression of Genes Involved in Growth Factor Signaling. <i>Pharmaceutical Research</i> , 2006, 23, 336-349.	1.7	25
67	μ -Naltrexol, a Peripherally Selective Opioid Antagonist that Inhibits Morphine-Induced Slowing of Gastrointestinal Transit: An Exploratory Study. <i>Pain Medicine</i> , 2011, 12, 1727-1737.	0.9	24
68	Genomics and drugs: finding the optimal drug for the right patient. , 1998, 15, 959-963.		23
69	Sequence alignments of the H(+)-dependent oligopeptide transporter family PTR: inferences on structure and function of the intestinal PET1 transporter. , 1997, 14, 388-400.		22
70	The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy. <i>Journal of Personalized Medicine</i> , 2012, 2, 175-191.	1.1	22
71	Evolutionary relationships among proteins probed by an iterative neighborhood cluster analysis (INCA). Alignment of bacteriorhodopsins with the yeast sequence YRO2. , 1997, 14, 1533-1541.		21
72	Genomic architecture of pharmacological efficacy and adverse events. <i>Pharmacogenomics</i> , 2014, 15, 2025-2048.	0.6	21

#	ARTICLE	IF	CITATIONS
73	Regulatory Polymorphisms in Human <i>DBH</i> Affect Peripheral Gene Expression and Sympathetic Activity. <i>Circulation Research</i> , 2014, 115, 1017-1025.	2.0	21
74	CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele). <i>Pharmacogenetics and Genomics</i> , 2019, 29, 39-47.	0.7	21
75	Design and Implementation of a Randomized Controlled Trial of Genomic Counseling for Patients with Chronic Disease. <i>Journal of Personalized Medicine</i> , 2014, 4, 1-19.	1.1	20
76	DRD2/CHRNA5 Interaction on Prefrontal Biology and Physiology during Working Memory. <i>PLoS ONE</i> , 2014, 9, e95997.	1.1	19
77	Drug Therapy and Personalized Health Care: Pharmacogenomics in Perspective. <i>Pharmaceutical Research</i> , 2008, 25, 2713-2719.	1.7	18
78	The epigenome, 4D nucleome and next-generation neuropsychiatric pharmacogenomics. <i>Pharmacogenomics</i> , 2015, 16, 1649-1669.	0.6	18
79	Interactions Between Regulatory Variants in <i>CYP7A1</i> (Cholesterol 7 α -Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002082.	1.6	18
80	Non-linear interactions between candidate genes of myocardial infarction revealed in mRNA expression profiles. <i>BMC Genomics</i> , 2016, 17, 738.	1.2	17
81	Genomics and personalized medicine. <i>International Journal of Pharmaceutics</i> , 2011, 415, 2-4.	2.6	16
82	Measuring cis-acting regulatory variants genome-wide: new insights into expression genetics and disease susceptibility. <i>Genome Medicine</i> , 2009, 1, 116.	3.6	15
83	Allele-Selective Transcriptome Recruitment to Polysomes Primed for Translation: Protein-Coding and Noncoding RNAs, and RNA Isoforms. <i>PLoS ONE</i> , 2015, 10, e0136798.	1.1	15
84	Combined genetic influence of the nicotinic receptor gene cluster CHRNA5/A3/B4 on nicotine dependence. <i>BMC Genomics</i> , 2018, 19, 826.	1.2	15
85	Molecular modeling of G-protein coupled receptor kinase 2: Docking and biochemical evaluation of inhibitors. <i>AAPS PharmSci</i> , 2000, 2, 9-21.	1.3	14
86	Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits. <i>PLoS ONE</i> , 2017, 12, e0179020.	1.1	14
87	5-Aza-2 β -deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting) Tj ETQq1 1 0,784314 rgBT /Over	1.0	13
88	6 β -naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice. <i>Life Sciences</i> , 2009, 85, 413-420.	2.0	12
89	Human Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine β -Hydroxylase Knockout Mice. <i>PLoS ONE</i> , 2016, 11, e0154864.	1.1	12
90	Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect. <i>Pharmacogenomics</i> , 2011, 12, 675-680.	0.6	11

#	ARTICLE	IF	CITATIONS
91	Testing Genetic Modifiers of Behavior and Response to Atomoxetine in Autism Spectrum Disorder with ADHD. <i>Journal of Developmental and Physical Disabilities</i> , 2018, 30, 355-371.	1.0	11
92	Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 22-30.	1.3	10
93	Regulatory Variants Modulate Protein Kinase C $\hat{\pm}$ (PRKCA) Gene Expression in Human Heart. <i>Pharmaceutical Research</i> , 2017, 34, 1648-1657.	1.7	10
94	Whole Transcriptome Profiling: An RNA-Seq Primer and Implications for Pharmacogenomics Research. <i>Clinical and Translational Science</i> , 2018, 11, 153-161.	1.5	10
95	Pharmacogenomics: Harbinger for the Era of Personalized Medicine?. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005, 5, 140-143.	3.4	9
96	The re-emerging concept of personalized healthcare. <i>Personalized Medicine</i> , 2008, 5, 457-469.	0.8	8
97	Gene-Environment Interactions Between Drugs, Transporters, Receptors, and Metabolizing Enzymes: Statins, SLCO1B1, and CYP3A4 as an Example. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2924-2929.	1.6	8
98	Analyzing allele specific RNA expression using mixture models. <i>BMC Genomics</i> , 2015, 16, 566.	1.2	8
99	Alpha-synuclein mRNA isoform formation and translation affected by polymorphism in the human SNCA 3'UTR. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 565-574.	0.6	8
100	Interpreting coronary artery disease GWAS results: A functional genomics approach assessing biological significance. <i>PLoS ONE</i> , 2022, 17, e0244904.	1.1	8
101	Bridging material and biological sciences: The legacy of Hans Peter Merkle. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 3-4.	2.0	7
102	Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management. <i>Molecules</i> , 2020, 25, 4163.	1.7	7
103	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. <i>BMC Medical Genomics</i> , 2018, 11, 55.	0.7	6
104	Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 280-289.	1.1	6
105	Regulatory polymorphisms in key candidate genes for disease susceptibility and drug response: a mandate for valid genetic biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 9-11.	1.5	5
106	Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 269-278.	0.7	5
107	Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. <i>Scientific Reports</i> , 2017, 7, 16068.	1.6	5
108	Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. <i>Pharmacogenomics Journal</i> , 2021, 21, 376-389.	0.9	5

#	ARTICLE	IF	CITATIONS
109	Network analysis using transitive closure: New methods for exploring networks. <i>Journal of Statistical Computation and Simulation</i> , 2006, 76, 539-551.	0.7	4
110	Significant association of <i>DRD2</i> enhancer variant rs12364283 with heroin addiction in a Pakistani population. <i>Annals of Human Genetics</i> , 2019, 83, 367-372.	0.3	4
111	Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Anticancer Research</i> , 2020, 40, 5707-5713.	0.5	4
112	Challenges of Immune Response Diversity in the Human Population Concerning New Tuberculosis Diagnostics, Therapies, and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 139.	1.8	4
113	Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs). <i>BMC Genomics</i> , 2015, 16, S8.	1.2	3
114	Pharmacological Prevention of Neonatal Opioid Withdrawal in a Pregnant Guinea Pig Model. <i>Frontiers in Pharmacology</i> , 2020, 11, 613328.	1.6	3
115	Personalized Therapeutics and Pharmacogenomics: Integral to Personalized Health Care. <i>Pharmaceutical Research</i> , 2017, 34, 1535-1538.	1.7	2
116	Cladograms with Path to Event (ClAPTE): A novel algorithm to detect associations between genotypes or phenotypes using phylogenies. <i>Computers in Biology and Medicine</i> , 2015, 58, 1-13.	3.9	1
117	Sulfatase 2 Is Associated with Steroid Resistance in Childhood Nephrotic Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 523.	1.0	1
118	How Specific Are "Target-Specific" Drugs? Celecoxib as a Case in Point. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2006, 6, 196-198.	3.4	1
119	Chemogenomics of Sensitivity and Resistance to Anticancer Drugs. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007, 5, 11-19.	0.3	0
120	Allelic mRNA expression of sortilin-1 (SORL1) mRNA in Alzheimer's autopsy brain tissues. <i>Neuroscience Letters</i> , 2008, 448, 120-124.	1.0	0
121	Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in <i>Psychopharmacology</i> 232, 305-314, 2014. <i>Psychopharmacology</i> , 2015, 232, 1493-1494.	1.5	0
122	Nicotine Dependence and the CHRNA5/CHRNA3/CHRNA4 Nicotinic Receptor Regulome. , 2019, , 347-353.		0
123	Association of Regulatory Genetic Variants for Protein Kinase C δ with Mortality and Drug Efficacy in Patients with Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 693-700.	1.3	0
124	CYP2D6 expression is regulated by polymorphisms that affect splicing and transcription: new biomarkers for CYP2D6 activity. <i>FASEB Journal</i> , 2013, 27, 663.6.	0.2	0
125	Low-Dose δ -Naltrexol Prevents Opioid Dependence Without Affecting Antinociception. <i>FASEB Journal</i> , 2022, 36, .	0.2	0